Sankyo Company, Limited

Citizen Watch Company, Ltd.

Ube Industries, Inc.

Nec Corporation

Cincinnati Children's Hospital Medical Center

Fukuda Denshi Co., Ltd.

Fukuda Densky Co, Ltd.

Hiroyuki Koike

Sadao Ishihara

Hiroaki Yanagisawa

Fujio Saito

Yasuhiro Morisawa

Mitsuru Kataoka

Takuro Kanazaki

Haruhiko Higuchi

Yasuteru Iijima

Fumitoshi Asai

Hiroshi Nishino

Yasuo Shimoji

Toshio Sada

Takao Yoshioka

Koichi Fujimoto

Hiroshi Mizuno

Yasuo Kitajima

Shigeki Miyake

Takeo Mutoh

Teruhiko Inoue

Teiichiro Koga

Atsuhiro Sugidachi

Akiko Ando

Yuichiro Yabe

Yoshiya Amemiya

Tatsuo Kokubu

Kunio Hiwada

Hidekuni Takahagi

Akira Yoshida

Naoki Tanaka

Norio Nakamura

Tomio Kimura

Shigeyoshi Nishino

Takeshi Oshima

Yoshio Tsujita

Ichiro Hayakawa

Hiroshi Kogen

Eiichi Kitazawa

Hiroshi Fukumi

Yasunori Tsuzaki

Yoshiya Muraki

Yasunobu Sato

Seiji Kumakura

Masafumi Yoshimoto

Koza Oda

Yoshio Iizuka

Hiroyoshi Horikoshi

Toshihiko Fujiwara

Shinsaku Kobayashi

Nobuyoshi Iwata

Takashi Kasai

Toshihiko Hashimoto

Mitsuo Sugiyama

Katsunori Takata

Takanori Takebe

Shinji Yoshioka

Kenji Yoneda

Ryo Iwamura

Taketoshi Ogawa

Jun-ichiro Kita

Kuniyuki Tomita

Hideki Miyazaki

Toshihiko Ikeda

Tomiyoshi Ito

Tatsuo Tanimoto

Nobuaki Kitahara

Yasuo Simoji

Hitoshi Nagahori

Nobuyuki Ookawa

Takeshi Oshmia

Hidekazu Masuko

Disclosed herein are hepato-biliary-pancreatic organoid ('HBPO' or “HBP organoid”) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

Hepato-biliary-pancreatic tissues and methods of making same

An electronic timepiece has a calendar advancement device resistant to external shock and capable of achieving date correction in a short time. A date dial advancement transducer ( ) is activated in response to a date dial drive signal generated by a 24-hour switch. A date advancement mechanism (a date gear train) ( ) employs a Geneva wheel for stabilizing the date dial ( ). A bounding restraint lever is regulated using an eccentric cam or the like provided coaxially with the Geneva wheel.

Electronic timepiece with calendar device

Electronic timepiece with calendar month-end non-correction device

Electronic watch with calendar

A cyclic amine derivative represented by the following formula: ##STR1## wherein R.sup.1 represents a substituted or unsubstituted phenyl group, R.sup.2 represents a substituted of unsubstituted C.sub.1 -C.sub.8 aliphatic acyl group, a substituted or unsubstituted benzoyl group or a C.sub.1 -C.sub.4 alkoxycarbonyl group, and R.sup.3 represents a substituted 3 to 7 membered saturated cyclic amino group which may form a fused ring; or pharmaceutically acceptable salts thereof. The compounds and salts have excellent platelet aggregation inhibitory action. They are useful for the treatment and prevention of such diseases as embolism, thrombosis or arteriosclerosis and for the preparation of pharmaceutical compositions for such uses.

Cyclic amine derivatives

A switch (201) is conjoined with a hand driving gear train (107) and provided with at least three or more contact groups (203, 204, 205) turned on at least once in each 24 hours. A calendar indicating member is updated according to an order of closing each contact. The matching between the time indicating and the calendar indicating can be accomplished when a user modifies the time display.

Electronic timepiece provided with a calendar

Compounds of formula (I): ##STR1## wherein: R.sup.1 represents a saturated heterocyclic group attached to the bond or group represented by A through a ring carbon atom; R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3a, R.sup.3b, R.sup.3c and R.sup.3d are hydrogen or various other groups or atoms; and A represents a single bond or an alkylene group having from 1 to 6 carbon atoms are serotonin 2 receptor antagonists and have the ability to inhibit the activity of squalene synthase. They can not only prevent and inhibit the development and progression of arteriosclerosis but can also inhibit thrombosis in arteriosclerotic lesions and can improve hemodynamics.

Diphenylethane compounds containing a saturated heterocyclic group,

An amino acid compound of the formula: R.sup.1 NH--CH(R.sup.2)--COHN--A--ONO.sub.2, wherein R.sup.1 represents a hydrogen atom, a C.sub.1 -C.sub.7 alkanoyl group, a C.sub.1 -C.sub.6 alkoxycarbonyl group, a C.sub.6 -C.sub.10 arylcarbonyl group, a C.sub.7 -C.sub.13 aralkylcarbonyl group, a C.sub.7 -C.sub.13 aralkyloxycarbonyl group or a 5- or 6-membered aromatic heterocyclic carbonyl group; R.sup.2 represents a substituted C.sub.1 -C.sub.6 alkyl group; and A represents a C.sub.2 -C.sub.5 alkylene group; and pharmacologically acceptable salts thereof. The amino acid compound has an excellent vasodilator action for collateral vessels and is useful for treating angina pectoris.

Amino acid derivatives

An angiotensin II antagonist of the formula: ##STR1## in which: R.sub.p.sup.1 represents hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl or C.sub.1 -C.sub.6 alkanoyl; R.sub.p.sup.2 represents a single bond, C.sub.1 -C.sub.4 alkylene or C.sub.1 -C.sub.4 alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are independently selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyl; R.sub.p.sup.5 represents hydrogen, C.sub.1 -C.sub.4 alkyl, phenyl, naphthyl, benzyl, diphenylmethyl, naphthylmethyl, alkanoyloxyalkyl, cycloalkanecarbonyloxyalkyl, alkoxycarbonyloxyalkyl, cycloalkyloxycarbonyloxyalkyl, (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl, (5-alkyl-2-oxo-1,3-dioxolen-4-yl)methyl or phthalaidyl; R.sub.p.sup.6 represents a carboxy or a tetrazol-5-yl; and X.sub.p represents an oxygen or sulfur, and pharmaceutically acceptable salts thereof. The compounds have hypotensive activity and can thus be used for the treatment and prophylaxis of hypertension.

Angiotensin II antagonist 1-biphenylmethylimidazole compounds and their

Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.sub.p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.

Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their

Compounds of formula (I) are provided: ##STR1## wherein: R.sup.1 represents an alkyl group; or a group of formula (II), (III), (IV) or (V): ##STR2## and wherein the groups R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are hydrogen or various organic groups; and pharmaceutically acceptable salts thereof; as well as methods for the preparation of such compounds and their use in the treatment and prophylaxis of hypercholesteremia and arteriosclerosis.

Amide and urea derivatives having anti-hypercholesteremic activity,

Thiazolidine derivatives of formula (I): ##STR1## (in which: R.sup.1, R.sup.2, R.sup.4, R.sup.5 are each hydrogen or alkyl; and R.sup.3 is hydrogen, aliphatic acyl, alkoxy-carbonyl, or arylcarbonyl and pharmaceutically acceptable salts thereof are anti-hypertensive agents and are useful in the treatment of obesity-related hypertension.

Thiazolidine derivatives having anti-hypertensive activity and their

Nitroxyalkylamide derivatives

Compounds of formula (I): ##STR1## [wherein: R.sup.1 is aryl; R.sup.2 is hydrogen, alkyl, alkoxy, halogen or cyano; R.sup.3 is a group of formula --B--NR.sup.4 R.sup.5, where R.sup.4 and R.sup.5 are independently hydrogen, alkyl or substituted alkyl or R.sup.4 and R.sup.5, together with the nitrogen to which they are attached, form a heterocycle, and B is alkylene or a group of formula --CH.sub.2 CH(OR.sup.6)CH.sub.2 --, where R.sup.6 is hydrogen, alkanoyl, substituted alkanoyl or arylcarbonyl, or a group of formula --D--R.sup.7, where D is a single bond or alkylene and R.sup.7 is a heterocycle; and A is alkylene; and pharmaceutically acceptable salts and esters thereof] are useful for the treatment and prevention of circulatory diseases and psychosis.

.alpha.-.omega.-diarylalkane compounds serotonin-2 receptor agonists

Growing community of inventors

Tokyo, Japan

Hiroyuki Koike